AbbVie

AbbVie’s mission is to discover and deliver innovative medicines and solutions that solve serious health issues today and address the medical challenges of tomorrow. We strive to have a remarkable impact on people’s lives across several key therapeutic areas –immunology, oncology, neuroscience, and eye care – and products and services in our Allergan Aesthetics portfolio. For more information about AbbVie, please visit us at www.abbvie.com. Follow @abbvie on X, Facebook, Instagram, YouTube, LinkedIn and Tik Tok.

1 North Waukegan Road
North Chicago, IL 60064

Visit website

Stock Symbol: ABBV
Stock Exchange: NYSE

Together, we break through.

Our principles are at the Heart of our Company. Operating as one AbbVie team, we care deeply for our patients, their families, our employees, and our communities. We strive to always do the right thing, pursuing the highest standards in quality, compliance, safety, and performance. In everything we do, we invest and innovate relentlessly to tackle unmet needs, creating new medicines and healthcare approaches for a healthier world.

How we work with each other and achieve results matters. That’s why we’ve been honored to receive some of the most prestigious ratings and recognitions in the industry, including being named on more than 40 Great Place to Work and Top Employer lists and FORTUNE “100 Best Companies to Work For.”

Click here to learn more about our principles.

NEWS

Pictured: Mark Cuban/Courtesy of Roy Rochlin/Getty

Business

Coherus to Offer 85% Discount for its Humira Biosimilar

The company’s Humira biosimilar Yusimry will launch in July with a $995 list price. Mark Cuban’s online pharmacy will sell it at a list price of $569.27 plus fees.

June 2, 2023

2 min read

Tristan Manalac

Pictured: Blue and white Pfizer sign on building/c

Drug Development

Pfizer’s Antibiotic Combo Clears Phase III, Shows Promise Against Multidrug Resistance

The company’s aztreonam-avibactam matched the cure rate of a meropenem-based regimen in patients with drug-resistant infections.

June 2, 2023

3 min read

Tristan Manalac

Pictured: AbbVie sign on a building/courtesy of Ad

Drug Development

AbbVie’s Rinvoq Maintains Durability in Phase II Lupus Study

The company’s blockbuster JAK inhibitor, alone or as a combination therapy, showed durable improvements in systemic lupus erythematosus disease activity at 48 weeks.

May 31, 2023

3 min read

Heather McKenzie

FDA

AbbVie, Genmab Score FDA Nod for DLBCL as Blood Cancer Space Heats Up

With Friday’s approval, Epkinly edges out Roche’s bi-specific antibody glofitamab, which is also being proposed for diffuse large B-cell lymphoma.

May 22, 2023

2 min read

Tristan Manalac

FDA

AbbVie Adds Crohn’s Disease to Rinvoq’s Growing List of Indications

Crohn’s disease is Rinvoq’s seventh approved indication and could potentially help AbbVie weather declining sales for its blockbuster biologic Humira.

May 19, 2023

2 min read

Tristan Manalac

Pictured: FDA Action Alert graphic/@Nicole Bean

Drug Development

FDA Action Alert: Krystal, Genmab/AbbVie, Pfizer and Intercept

The FDA has four events lined up this week, including a target action date for Krystal Biotech’s gene therapy for a rare skin disease and an adcomm meeting for Pfizer’s RSV vaccine candidate.

May 11, 2023

5 min read

Tristan Manalac

Business

Humira Sales Down 25% as AbbVie Cuts Two Programs

As Humira global revenues fall 25%, AbbVie looks to Rinvoq and Skyrizi to fill in the gap. The company also announced it is cutting cystic fibrosis and Crohn’s disease candidates.

April 28, 2023

2 min read

Kate Goodwin

Drug Development

AbbVie’s Migraine Drug Scores Another Phase III Win

AbbVie shared more positive results for its migraine prevention drug, Qulipta, just three days after FDA approval to expand its label.

April 21, 2023

2 min read

Kate Goodwin